Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | THPO | P40225 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7112386 | 0.92 | PTGS2 (1.00) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14747811 | 0.88 | PTGS2 (0.87) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| Sc-560 SCHEMBL676921 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7113069 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6266112 | 0.86 | PTGS2 (0.87) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5148900 | 0.86 | PTGS2 (0.87) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8292733 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5148973 | 0.86 | PTGS2 (0.87) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5147944 | 0.83 | PTGS2 (0.81) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5148706 | 0.83 | PTGS2 (0.81) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790725-B2 | Thiazolidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1426366-A1 | THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | PTGS2 2349/4885PTGS1 1656/4885CYP1A2 1009/4885 |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | DPP4, DPP7, DPP3 | PTGS2 2629/4885PTGS1 795/4885CYP1A2 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.